RxDoctor Payments Data

Karin True, MD

Nephrology · Chapel Hill, NCNPI 1730110065

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (47.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 80.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $1,555 and has fallen 80.6% since, to $302 in 2025.

$2,327in general payments, 2019–2025

Across 10 payments — averaging $232.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • One Lambda, Inc.$146
  • Sanofi-aventis U.S. LLC$131
  • GSK$81
  • OPKO Pharmaceuticals, LLC$75
  • Fresenius USA Marketing, Inc.$25
$220,398in research payments, 2019–2025

Across 3 payments — averaging $73,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mallinckrodt Hospital Products Inc.$170K
  • Mallinckrodt Enterprises LLC$50K

What the payments were for

  • Speaking & faculty fees$75032%
  • Travel & lodging$1,09947%
  • Food & beverage$45820%
  • Education$201%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck5$1,869
One Lambda, Inc.1$146
Sanofi-aventis U.S. LLC1$131
GSK1$81
OPKO Pharmaceuticals, LLC1$75
Fresenius USA Marketing, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,327 in reported general payments places this provider in the 65th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,979
Medicare patients
117
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$19,125
JardianceEmpagliflozin11$18,952
Posaconazole13$17,203
EliquisApixaban16$8,996
Mycophenolic AcidMycophenolate Sodium25$2,405
Cyclosporine ModifiedCyclosporine, Modified13$2,284
Cinacalcet Hcl18$2,065
Calcitriol29$1,236
Tacrolimus11$760
ValacyclovirValacyclovir Hcl14$736
Pravastatin Sodium35$673
Carvedilol62$669
Atorvastatin Calcium109$666
Gabapentin43$566
Omeprazole51$490

Paid to pharmacies, not to this prescriber.

Other nephrology in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →